Corcept Mifepristone Phase III Trials For Depression Underway – IPO
Executive Summary
Corcept Therapeutics expects to complete analysis of Phase III data on mifepristone for psychotic major depression by the end of 2003
You may also be interested in...
Corcept To Test Sluggish IPO Market For Biotechs
Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10
Corcept To Test Sluggish IPO Market For Biotechs
Corcept Therapeutics will test the sluggish market for biopharmaceutical initial public offerings with an IPO slated for June 10
Mifeprex Label Allows Use By Physicians Not Trained In Surgical Abortion
The Population Council and Danco Labs will conduct a postmarketing safety study to compare outcomes for Mifeprex (mifepristone) patients treated by physicians trained in surgical abortion versus those treated by physicians not trained in abortion.